Purpura Diagnosis and Management

Introduction to Purpura

The American Society of Hematology recommends that patients with thrombocytopenic purpura undergo a complete blood count with platelet count as the essential first test 1
The presence of thrombocytopenia, characterized by a platelet count typically <30,000, is a key feature of thrombocytopenic purpura 1
The American College of Rheumatology suggests that patients with vasculitic purpura may have systemic symptoms, such as fever and arthralgia, and organ involvement, including kidney and GI tract involvement 6

The initial assessment of purpura should determine if it is palpable or non-palpable and assess the distribution pattern, with associated symptoms such as fever, joint pain, and abdominal pain 6
A peripheral blood smear examination is essential for diagnosing thrombocytopenic purpura, with normal red and white blood cell morphology on peripheral smear 1, 3
Coagulation studies, including prothrombin time and activated partial thromboplastin time, may be necessary to evaluate coagulation disorders 1

The American Society of Hematology states that thrombocytopenic purpura is often associated with idiopathic thrombocytopenic purpura (ITP) and drug-induced thrombocytopenia 1, 5
Vasculitic purpura is typically associated with leukocytoclastic vasculitis, which can be seen in ANCA-associated vasculitides, IgA vasculitis, and mixed cryoglobulinemia syndrome 6
Mixed cryoglobulinemia syndrome is characterized by the presence of cryoglobulins, low complement C4 fraction, and cutaneous leukocytoclastic vasculitis, often associated with HCV infection 6

The American Society of Hematology recommends that patients with ITP and platelet counts >30,000 and minimal symptoms be observed without specific treatment, while those with platelet counts <20,000 and significant mucous membrane bleeding receive treatment with IVIg or glucocorticoids 1
For life-threatening bleeding, hospitalization, high-dose parenteral glucocorticoids, IVIg, and platelet transfusions may be necessary 1
The European League Against Rheumatism suggests that patients with mixed cryoglobulinemia syndrome undergo comprehensive evaluation for HCV and other associated conditions, with treatment directed at the underlying cause, such as HCV therapy, and immunosuppression for severe organ involvement 6